Incidensen af bivirkninger af sværhedsgrad 3 eller 4 er højere hos patienter med moderat nyreinsufficiens (creatininclearance 30 – 50 ml/ min ved baseline), sammenlignet med den samlede population.
The incidence of grade 3 or 4 adverse reactions in patients with moderate renal impairment (creatinine clearance 30-50 ml/ min at baseline) is increased compared to the overall population.